MA
SCLN

MUFG Americas’s Sciclone Pharmaceuticals Inc SCLN Stock Holding History

MUFG Americas’s Portfolio SCLN Stock Details SCLN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		– Sell
-370
Closed -$4K – 1212
2016
Q3 		$4K Sell
370
-190
-34% -$2.07K ﹤0.01% 1018
2016
Q2 		$7K Hold
560
– – ﹤0.01% 957
2016
Q1 		$6K Sell
560
-390
-41% -$3.47K ﹤0.01% 928
2015
Q4 		$9K Buy
+950
New +$7.95K ﹤0.01% 859

Other funds holding SCLN

BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
NI
Numeric Investors Boston, Massachusetts $13.7B AUM 28.88% 1-Year Est. Return

MUFG Americas's SCLN Position: Q4 2016 in Review

MUFG Americas sold out of Sciclone Pharmaceuticals Inc (SCLN) in Q4 2016, closing a stake of 370 shares — an estimated $4K sold.

MUFG Americas first reported a position in SCLN in Q4 2015 and held it in 4 quarters. The position peaked at $9K in Q4 2015. 153 funds tracked by Wall St. Rank hold SCLN as of Q4 2016.

  • MUFG Americas reported no remaining Sciclone Pharmaceuticals Inc position as of Q4 2016 after selling out during the quarter.
  • MUFG Americas sold 370 Sciclone Pharmaceuticals Inc shares in Q4 2016, an estimated $4K.
  • MUFG Americas first reported a position in Sciclone Pharmaceuticals Inc in Q4 2015 and held it in 4 quarters.
  • MUFG Americas's Sciclone Pharmaceuticals Inc position peaked at $9K in Q4 2015.
  • 153 funds tracked by Wall St. Rank held Sciclone Pharmaceuticals Inc as of Q4 2016.

Based on MUFG Americas's 13F filing for Q4 2016, filed 8 Feb 2017.